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Background/Aims: We investigated whether inflammatory 
markers such as neutrophil-lymphocyte ratio (NLR) and plate-
let-lymphocyte ratio (PLR) independently and in combination 
would be significant prognostic factors for survival in patients 
with locally advanced pancreatic cancer. Methods: A total of 
497 patients with locally advanced pancreatic cancer who 
received neoadjuvant or definitive chemoradiotherapy from 
2005 to 2015 were evaluated. We divided the patients into 
groups according to the median values of NLR and PLR: 
NLR<1.89 (n=156), NLR≥1.89 (n=341), PLR <149 (n=248) 
and PLR ≥149 (n=249). Results: For NLR <1.89 and ≥1.89 
groups, respectively, the 1-year overall survival (OS) rates 
were 73.2% and 60.8% (p<0.001) and 1-year progression-
free survival (PFS) rates were 43.9% and 31.3% (p<0.001). 
For PLR <149 and ≥149 groups, respectively, the 1-year 
OS rates were 68.1% and 61.3% (p=0.029) and 1-year PFS 
rates were 37.9% and 32.5% (p=0.027). Patients with both 
high NLR and high PLR showed the worst OS and PFS rates 
compared with those with both lower NLR and lower PLR. 
Conclusions: Elevated pretreatment NLR and PLR indepen-
dently and in combination significantly predicted poor OS 
and PFS. (Gut Liver 2018;12:342-352)
Key Words: Pancreatic neoplasms; Prognosis; Neutrophils; 
Platelet count; Lymphocyte count
INTRODUCTION
Among major solid tumors, pancreatic cancer is well known 
for its poor prognosis.1 Although surgical treatment is the treat-
ment of choice for pancreatic cancer, only 20% of patients are 
candidates for curative resection.2 Pancreatic cancer is consid-
ered to be resectable when the tumor is not in contact with ma-
jor arteries (celiac axis, superior mesenteric artery, or common 
hepatic artery) or major veins (superior mesenteric vein or portal 
vein). If the patient has locally advanced, such as unresectable 
or borderline resectable, pancreatic cancer, chemotherapy or de-
finitive or preoperative concurrent chemoradiotherapy (CCRT) is 
recommended, and the survival is much poorer than those with 
resectable tumors.3 Thus, it is important to find the prognostic 
factors for patients with locally advanced pancreatic cancer and 
set an optimal treatment plan.
Recently, the notion that the outcome of cancer patients is af-
fected not only by tumor characteristics but also by host-related 
factors has gained much attention. Host factors such as age, 
sex, performance status, and inflammatory status have been 
identified as significant prognostic factors in many reports.4-6 
As it has become apparent that cancer-associated inflamma-
tion is a key determinant of disease progression and survival 
for cancer patients, there has been much interest in the relation-
ship between patient prognosis and inflammatory hematologic 
markers.7,8 Among inflammatory hematologic markers, the 
neutrophil-lymphocyte ratio (NLR) and the platelet-lymphocyte 
ratio (PLR) are well-known hematologic markers, and studies 
have suggested that NLR and PLR are associated with the out-
come of cancer patients.5,7
Although there are many studies reporting the significance 
of NLR and PLR as prognostic factors in pancreatic cancer, al-
most none have shown the efficacy of NLR and PLR in patients 
with locally advanced pancreatic cancer receiving CCRT.7,9-13 
Thus, this study aimed to investigate whether NLR and PLR are 
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associated with the survival outcomes of patients with locally 
advanced pancreatic cancer treated with CCRT.
MATERIALS AND METHODS
1. Patients
We retrospectively examined the medical records of patients 
with locally advanced pancreatic cancer who had undergone 
neoadjuvant or definitive CCRT from January 2005 to Decem-
ber 2015. All patients who had previously received any other 
treatment, patients who had been diagnosed with a double pri-
mary malignancy, patients with distant metastasis at diagnosis, 
patients who had received RT alone or under 20 Gy, patients 
with no follow-up imaging, and patients with a neuroendocrine 
tumor were excluded. Finally, 497 patients were included in the 
analysis. We retrospectively collected and analyzed patient data, 
including clinical and laboratory information including white 
blood cell differential counts and platelet counts. The NLR was 
calculated by dividing the neutrophil count by the lymphocyte 
count, and the PLR was calculated by dividing the platelet 
count by the lymphocyte count. All NLR and PLR values were 
measured before the start of treatment within 2 weeks. The re-
sectability of pancreatic tumors was determined based on imag-
ing studies including computed tomography (CT) and magnetic 
resonance imaging (MRI).
The study was approved by the Institutional Review Board of 
Severance Hospital (IRB No. 2017-3183-01) and performed in 
accordance with the principles of the Declaration of Helsinki. 
The informed consent was waived for this retrospective study.
2. Treatment
All patients included in this study received initial preoperative 
or definitive CCRT.
For RT, CT simulation was performed with intravenous con-
trast and four-dimensional CT when possible, and respiration 
training was done to minimize the respiration motion. The 
primary tumor and involved lymph nodes were set as the gross 
tumor volume (GTV). The internal target volume (ITV) was de-
lineated when possible, and the planning target volume (PTV) 
was defined as the GTV or ITV plus a 5-mm margin. A total 
of 281 patients (56.5%) received three-dimensional conformal 
RT (3DCRT), and the remaining 216 patients (43.5%) received 
intensity-modulated radiotherapy (IMRT). The most commonly 
used dose scheme was 50.4 Gy in 28 patients for 3DCRT pa-
tients and 58.42 Gy in 23 fractions for IMRT patients.
For chemotherapy, various chemotherapy regimens were 
used: (1) 1,000 mg/m2 gemcitabine weekly (days 1, 8, and 15) 
followed by a 1-week rest period; (2) 75 mg/m2 cisplatin on 
day 1 of each 28-day cycle combined with weekly 1,000 mg/m2 
gemcitabine; (3) 500 mg/m2 fluorouracil weekly; (4) 850 mg/m2 
capecitabine twice daily; (5) 40 mg/m2 titanium silicate-1 twice 
daily from days 1 to 14 and from days 22 to 35; and (6) 0.5 g 
tegafur/uracil three times daily. The primary aim was to admin-
ister full-dose chemotherapy.
3. Response assessment
Routine follow-up was performed at 1 and 3 months after 
CCRT and routinely after that. The Response Evaluation Criteria 
in Solid Tumors were used to evaluate the treatment response. 
The progression of the disease was observed based on imaging 
studies such as CT or MRI. The recurrence of tumor, increased 
size of primary tumor, or development of regional or distant 
metastasis was defined as progression.
4. Statistical analysis
The primary endpoint of our study was overall survival (OS), 
and the secondary endpoints were progression-free survival 
(PFS), local failure-free rate (LFFR), and distant failure-free rate 
(DFFR). All endpoints were calculated from the first date of 
treatment to the date of the event. The Kaplan-Meier methods 
and log-rank test were used to calculate the cumulative prob-
abilities of OS, PFS, LFFR, and DFFR. Univariate and multivari-
ate analyses were performed using the Cox proportional hazards 
model. Multivariate analysis was performed using the statisti-
cally significant factors proven using univariate analysis. The 
SPSS version 23.0 (IBM Corp., Armonk, NY, USA) was used for 
all analyses.
RESULTS
1. Patient and tumor characteristics
Patient and tumor characteristics are shown in Table 1. We 
divided the patients into groups based on receiver operating 
characteristics value for the pretreatment NLR and the median 
value for PLR. The value of NLR and PLR before treatment were 
1.89 and 149 respectively. For the two groups divided by the 
receiver operating characteristics value of NLR, characteristics 
such as age, sex, Eastern Cooperative Oncology Group (ECOG) 
status, pathology, tumor stage (T stage), node stage (N stage), 
chemotherapy regimen, resectability and RT dose did not show 
significant difference between the two groups. However, there 
were more patients with tumor size >3.1 cm and less patients 
with pancreatic head tumor in the higher NLR group. Regard-
ing the two groups divided by the median value of PLR, most 
patient and tumor characteristics did not differ, except for the 
subsite and T stage. More patients had a pancreas head tumor 
in the higher PLR group. However, more patients had T4 stage 
disease in the lower PLR group.
2. Overall survival
The median follow-up was 19.3 months (range, 4.8 to 128.5 
months). The median OS was 15.7 months. The OS was sig-
nificantly lower in the NLR 1.89 group than the NLR <1.89 
group (Fig. 1A). The 1-year OS rates were 73.2% and 60.8% for 
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Table 1. Patient and Tumor Characteristics
Characteristic
Total
(n=497)
NLR<1.89
(n=156)
NLR1.89
(n=341)
p-value
PLR<149
(n=248)
PLR149
(n=249)
p-value
Age, yr 64 (35–88) 62 (35–83) 64 (35–88) 0.198 63 (35–88) 64 (35–87) 0.682
    64 272 (54.7)  92 (59.0) 180 (52.8) 138 (55.6) 134 (53.8)
    >64 225 (45.3) 64 (41.0) 161 (47.2) 110 (44.4) 115 (46.2)
Sex 0.091 0.687
    Female 202 (40.6) 72 (46.2) 130 (38.1) 103 (41.5)  99 (39.8)
    Male 295 (59.4) 84 (53.8) 211 (61.9) 145 (58.5) 150 (60.2)
ECOG 0.924* 0.374*
    ECOG 0 131 (26.4) 41 (26.3) 90 (26.4) 71 (28.6)  60 (24.1)
    ECOG 1 358 (72.0) 113 (72.4) 245 (71.8) 172 (69.4) 186 (74.7)
    ECOG 2 8 (1.6) 2 (1.3) 6 (1.8) 5 (2.0) 3 (1.2)
Pathology 0.157* 0.517*
    Adenoca 413 (83.1) 135 (86.5) 278 (81.5) 209 (84.3) 204 (81.9)
    Adenosquamous 
      carcinoma 
5 (1.0) 0 5 (1.5) 3 (1.2)  2 (0.8)
    Poor differentiated 5 (1.0) 0 5 (1.5) 1 (0.4)  4 (1.6)
    Unknown 74 (14.9) 21 (13.5) 53 (15.5) 35 (14.1) 39 (15.7)
Subsite 0.014 0.003
    Head 345 (69.4) 120 (76.9) 225 (66.0) 157 (63.3) 188 (75.5)
    Not head 152 (30.6) 36 (23.1) 116 (34.0) 91 (36.7)  61 (24.5)
Clinical T stage 0.277* 0.013*
    T1  7 (1.4) 4 (2.6) 3 (0.9) 3 (1.2) 4 (1.6)
    T2 33 (6.6) 8 (5.1) 25 (7.3) 12 (4.8) 21 (8.4)
    T3 204 (41.0) 69 (44.2) 135 (39.6) 89 (35.9) 115 (46.2)
    T4 253 (50.9) 75 (48.1) 178 (52.2) 144 (58.1) 109 (43.8)
Clinical N stage 0.584 0.826
    N0 297 (59.8) 96 (61.5) 201 (58.9) 147 (59.3) 150 (60.2)
    N1 200 (40.2) 60 (38.5) 140 (41.1) 101 (40.7) 99 (39.8)
Tumor size, cm 3.10 (1.20–9.00) 3.00 (1.20–6.00) 3.30 (1.20–9.00) 0.006 3.20 (1.20–9.00) 3.00 (1.20–9.00) 0.346
    3.1 251 (50.5) 93 (59.6) 158 (46.3) 120 (48.4) 131 (52.6)
    >3.1 246 (49.5) 63 (40.4) 183 (53.7) 128 (51.6) 118 (47.4)
Resectability 0.132 0.049
    Unresectable 378 (76.1) 112 (71.8) 266 (78.0) 198 (79.8) 180 (72.3)
    Borderline 119 (23.9) 44 (28.2) 75 (22.0) 50 (20.2) 69 (27.7)
Chemotherapy regimen 0.668 0.501
    Gemcitabine based 251 (50.5) 81 (51.9) 170 (49.9) 129 (52.0) 122 (49.0)
    Not gemcitabine based 246 (49.5) 75 (48.1) 171 (50.1) 119 (48.0) 127 (51.0)
CA 19-9 304.5 (0–20,000) 211.80 (0.10–20,000) 374.00 (0–20000) 0.031 305.0 (0.10–20,000) 304.0 (0–20,000) 0.893
    304.5 247 (49.9) 89 (57.1) 158 (46.6) 122 (49.6) 125 (50.2)
    >304.5 248 (50.1) 67 (42.9) 181 (53.4) 124 (50.4) 124 (49.8)
RT modality 0.876 0.826
    3DCRT 281 (56.5) 89 (57.1) 192 (56.3) 139 (56.0) 142 (57.0)
    IMRT+TOMO 216 (43.5) 67 (42.9) 149 (43.7) 109 (44.0) 107 (43.0)
TD EQD2 49.56 (24.42–64.31) 49.56 (38.44–62.00) 49.56 (24.42–64.31) 49.56 (24.42–64.31) 49.56 (42.47–62.00)
Data are presented median (range) or number (%).
NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; ECOG, Eastern Cooperative Oncology Group; CA, carbohydrate antigen; RT, ra-
diotherapy; 3DCRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiation therapy; TOMO, tomotherapy; TD, total dose; 
EQD2, equivalent dose in 2 Gy fractions. 
*Fisher exact test.
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NLR <1.89 and NLR 1.89 groups, respectively (p<0.001). The 
OS also showed a significant difference when the patients were 
divided by the median PLR value (Fig. 1B). The 1-year OS rates 
were 68.1% and 61.3% for PLR <149 and PLR 149 groups, re-
spectively (p=0.029).
We divided the patients into three groups according to both 
the NLR and PLR. Group A included patients with both low NLR 
and low PLR (n=113), group B included patients with either 
high NLR or high PLR (n=178), and group C included patients 
with both high NLR and high PLR (n=206). The 1-year OS rates 
showed difference between the three groups: 73.3%, 65.9%, and 
58.9% for groups A, B, and C, respectively (p=0.001) (Fig. 1C). 
Although the OS rates were not significantly different between 
groups A and B, the OS rate of group C was significantly lower 
than those of groups A and B. 
As shown in Tables 2-4, univariate analysis for OS showed 
that age, sex, ECOG status, tumor size, resectability, CA 19-9 
level, NLR, PLR, and grouping of NLR and PLR were significant 
prognostic factors. Multivariate analysis was also performed 
and tumor size >3.1 cm (HR, 1.35; 95% CI, 1.09 to 1.66; 
p=0.005), CA 19-9 >304.5 U/mL (HR, 1.32; 95% CI, 1.08 to 1.61; 
p=0.006), NLR 1.89 (HR, 1.40; 95% CI, 1.12 to 1.75; p=0.003) 
and PLR 149 (HR, 1.35; 95% CI, 1.11 to 1.65; p=0.003) proved 
to be significant adverse factors for OS. The significant benefi-
cial factors for OS were ECOG score 0 (HR, 0.40; 95% CI, 0.19 to 
0.84; p=0.016) and ECOG score 1 (HR, 0.48; 95% CI, 0.24 to 0.98; 
p=0.046) compared with ECOG score 2 and borderline resectable 
tumor (HR, 0.62; 95% CI, 0.47 to 0.81; p<0.001). In addition, 
both lower NLR and lower PLR compared with both higher NLR 
and higher LR (HR, 0.62; 95% CI, 0.47 to 0.81; p=0.001) and 
either higher NLR or higher PLR compared with both higher 
values (HR, 0.73; 95% CI, 0.58 to 0.91; p=0.007) proved to be 
beneficial factors for OS. 
We additionally analyzed the 1-year OS rates of different 
subgroups. Overall, 105 patients (21.1%) had undergone sur-
gery after CCRT. Fifty-two patients (13.8%) in the unresectable 
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Fig. 1. Kaplan-Meier estimates of the overall survival according to 
neutrophil-lymphocyte ratios (NLRs) 1.89 or <1.89 (A), platelet-
lymphocyte ratios (PLRs) 149 or <149 (B), and groups A, B, or C (C).
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group and 53 (44.5%) in the borderline resectable group had 
undergone surgery. The 1-year OS rates were 87.4% for the sur-
gery group and 58.2% for the non-surgery group, respectively 
(p<0.001).
3. Progression-free survival
The PFS showed a significant difference between the groups 
divided by NLR and PLR values. The 1-year PFS rates were 
43.9% and 31.3% for NLR <1.89 and NLR 1.89 groups, respec-
tively (p<0.001) (Fig. 2A). For PLR, the 1-year PFS rates were 
37.9% and 32.5% for PLR <149 and PLR 149 groups, respec-
tively (p=0.027) (Fig. 2B). We also examined the PFS for groups 
A, B, and C, with similar results as those for OS. The 1-year 
PFS rates for groups A, B, and C were 41.7%, 38.5%, and 29%, 
respectively (p<0.001) (Fig. 2C). Although there was no signifi-
cant difference in PFS between groups A and B, the PFS rate of 
group C was significantly lower than those of groups A and B.
On univariate analysis, sex, tumor size, CA 19-9 level, NLR, 
PLR, and grouping of NLR and PLR proved to be significant 
prognostic factors for PFS (Table 2-4). Among these factors, 
tumor size >3.1 cm (HR, 1.39; 95% CI, 1.15 to 1.69; p=0.001), 
CA19-9 >304.5 U/mL (HR, 1.35; 95% CI, 1.11 to 1.63; p=0.002), 
NLR 1.89 (HR, 1.44; 95% CI, 1.16 to 1.78; p=0.001), and PLR 
149 (HR, 1.28; 95% CI, 1.06 to 1.56; p=0.009) proved to be 
significant adverse factors for PFS. Significant favorable factors 
for PFS was both lower NLR and lower PLR compared with both 
higher NLR and higher PLR (HR, 0.63; 95% CI, 0.49 to 0.982; 
p=0.001) and either higher NLR or higher PLR compared with 
both higher values (HR, 0.69; 95% CI, 0.56 to 0.86; p=0.001).
4. Local failure-free rate and distant failure-free rate
When the patients were divided into two groups according to 
NLR, there was a significant difference for both LFFR and DFFR. 
The 1-year LFFR was 56.9% and 42.4% (p=0.03) and the 1-year 
DFFR was 539.2% and 44.0% (p=0.001) for NLR <1.89 and NLR 
1.89 groups, respectively (Fig. 3).
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Fig. 2. Kaplan-Meier estimates of progression-free survival ac-
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When the patients were divided by a PLR value of 149, there 
was no significant difference in either LFFR or DFFR. The 1-year 
LFFR was 50.2% and 43.4% (p=0.096) and the 1-year DFFR 
was 52.7% and 45.1% (p=0.102) for PLR <149 and PLR 149 
groups, respectively (Fig. 4). 
DISCUSSION
It is well known that tumor characteristics such as tumor 
size, tumor stage, and CA 19-9 level are considered meaning-
ful factors to predict a pancreatic cancer patient’s prognosis.14,15 
Recently, other studies have suggested that inflammation is as-
sociated with a poor prognosis in cancer patients.16,17 This study 
aimed to investigate the role of NLR and PLR in predicting the 
prognosis of patients with locally advanced pancreatic cancer 
who had undergone preoperative or definitive CCRT. Our results 
showed that patients with high NLR or PLR showed worse OS 
and PFS than those with lower NLR or PLR. When both values 
were taken into consideration, the group with both high NLR 
and high PLR showed the worst OS and PFS.
Many previous reports have shown the prognostic value of 
NLR and PLR and their significance as prognostic markers is be-
coming increasingly important. For example, a study with 403 
advanced pancreatic cancer patients reported that NLR 3.1 was 
a significant adverse factor for OS.18 Another study showed that 
NLR 3.3 was a negative factor for 67 elderly patients with un-
resectable pancreatic cancer, and other studies have shown NLR 
>5, NLR 2.551, and NLR 2.0 as significant prognostic values 
Fig. 3. Kaplan-Meier estimates of local failure-free rate (A) and distant failure-free rate (B) according to neutrophil-lymphocyte ratios (NLRs) 1.89 
or <1.89.
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Fig. 4. Kaplan-Meier estimates of local failure-free rate (A) and distant failure-free rate (B) according to platelet-lymphocyte ratios (PLRs) 149 or 
<149.
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for OS.7,9,11,19-21 PLR 126 was an important prognostic factor in 
a study involving 321 locally advanced and metastatic pancre-
atic cancer patients.4 Other studies have shown PLR 208.1, PLR 
200, and PLR >150 to be significant prognostic markers.7,9,13 
Although reports concerning PLR are less common in pancreatic 
cancer than those relating to NLR, it has been reported to be a 
prognostic factor in many other malignancies.22,23 In our study, 
both NLR and PLR proved to be a useful prognostic factor for 
both OS and PFS.
Currently, there is no consensus on the cutoff value of NLR 
and PLR, and thus, various cutoff values were used in previous 
studies. In some studies, the receiver operating characteristic 
curve was used for determining the cutoff value, and in some 
studies, median values were used.4,9,18,21,24 Some other studies 
have used cutoff values of 5 for NLR and 150 for PLR.13,19,25,26 
Our study set the cutoff values of NLR and PLR using their me-
dian values.
In this study, we additionally analyzed OS and PFS taking 
both NLR and PLR into consideration. The group of patients 
with both high NLR and high PLR showed the worst OS and 
PFS. To the best of our knowledge, this is the first study to in-
corporate both values into the analysis, and these results may 
aid in adequately determining the prognosis in patients with lo-
cally advanced pancreatic cancer.
Currently, the mechanisms responsible for high NLR and 
PLR being related to poor outcomes of cancer patients are not 
entirely understood. What is known is that inflammation sta-
tus promotes tumor proliferation and helps the survival of the 
malignant tumor.27 Furthermore, factors related to inflamma-
tion stimulate angiogenesis of the malignant tumor, invasion, 
and metastasis.28 As NLR and PLR represent the inflammation 
status of the host, a high NLR and PLR can be related to a poor 
prognosis for cancer patients. A high NLR represents both an 
elevated level of neutrophils and a decreased level of lympho-
cytes. Lymphocytes are known to mediate the anti-tumor re-
sponse and neutrophils are known to release cytokines, such as 
interleukins-1 and -6, and tumor necrosis factor, which promote 
cancer growth, angiogenesis, and metastasis.29 Therefore, a high 
NLR, in which a decreased lymphocyte count can be connected 
to a decreased immune response, and an elevated neutrophil 
count, which can be related to tumor progression, has the po-
tential to be a significant adverse prognostic factor for cancer 
patients.
There are several limitations in our study. First, as this is a 
retrospective study, the heterogeneity of the patients and treat-
ment may have affected the results. Second, although neutro-
phil and lymphocyte counts can be influenced by infection, 
drugs, or other factors, we did not consider these factors, which 
may have biased the results. However, beyond these limitations, 
this study also has several strengths. Although there are many 
reports on inflammation and prognosis, the number of patients 
included in this study is one of the largest in a single institu-
tion. In addition, only the patients who received preoperative 
or definitive CCRT as initial treatment in our institution were 
included, which may have reduced some bias. Furthermore, NLR 
or PLR can be easily measured using peripheral blood samples, 
which is excellent for its usefulness as a prognostic marker.
In summary, this study showed that higher NLR or PLR is re-
lated to poor OS and PFS and high NLR is related to poor LFFR 
and DFFR. Furthermore, when both NLR and PLR values were 
high, the results were the worst for OS and PFS. Based on these 
results, parameters showing systemic inflammation such as NLR 
and PLR can be useful markers for predicting the prognosis for 
advanced pancreatic cancer patients. Further studies will be 
needed to validate the usefulness and effectiveness of these in-
flammatory markers in advanced pancreatic cancer patients.
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